FTSE 100 news / Companies and sectors / GSK / 9 October 2026
GSK (GSK): news on Friday 9 October 2026
+2.0 slightly positive
Coverage was dominated by GSK's Viola Davis shingles campaign, plus positive news on ViiV's HIV trial and a blood-cancer acquisition. Share price weakness and a JP Morgan Sell rating held the balance back.
What drove it
- shingles campaign
- ViiV HIV trial
- share price weakness
The 21 stories
- +10.0 GSK’s ViiV says long-acting HIV treatment meets key Phase IIIb endpoint
ViiV long-acting HIV treatment meets Phase IIIb endpoint - +6.7 Can GSK plc (LSE:GSK) strengthen its blood-cancer pipeline after this week's T cell engager acquisition?
T cell engager acquisition strengthens blood-cancer pipeline - −6.7 GSK plc : Gets a Sell rating from JP Morgan
JP Morgan Sell rating - +5.8 Bavarian Nordic CFO says latest guidance upgrade vindicates GSK vaccine deal
Bavarian Nordic upgrade said to vindicate GSK vaccine deal - −5.0 GSK shares drop more than 2% after adding a new hepatology candidate amid persistent selling
Shares fall over 2% despite new hepatology candidate - −5.0 GSK shares technical analysis: GBX1,765 support faces pressure from sellers
Technical analysis shows support under selling pressure - +4.2 Viola Davis partners with GSK to educate adults 50 and older about their shingles risk
Viola Davis partnership for GSK shingles campaign - +4.2 Viola Davis Raises Shingles Awareness With GSK Campaign
Celebrity partnership raises shingles awareness for GSK - +3.7 Viola Davis partners with GSK to raise shingles awareness for adults 50+ in new health campaign.
Campaign partnership for adults 50+ - +3.3 Viola Davis Recalls ‘Debilitating Pain’ Due to Shingles and Learning the ‘Key to Aging Beautifully’ (Exclusive)
Shingles awareness campaign coverage - +3.3 Viola Davis Is Done Powering Through Her Shingles Pain
Shingles awareness coverage tied to GSK campaign - +3.3 Viola Davis opens up on shingles pain and aging beautifully
Celebrity shingles awareness linked to GSK campaign - +3.0 "Shingles, actually" our disease education campaign
GSK's own shingles education campaign - −2.5 GSK launches shingles campaign: stock after-hours at EUR 20.55, down 2.10 percent
Shingles campaign launch but shares down after hours - +2.5 RSV Awareness Month: Why older adults should take this virus seriously - sponsored by GSK
GSK-sponsored RSV awareness content - +2.5 GSK Passive Income Stock Draws ISA Buyers Despite Cost-Savings Push - Financial-News.co.uk
Income appeal for ISA buyers despite cost-savings push - +1.7 Tesco appoints GSK (GSK) director Wendy Becker to a non-executive board role.
GSK director gains Tesco board role, mildly positive - +1.7 GSK reported Cabenuva trial success. GSK stock trades 1.38 percent below its prior close.
Cabenuva trial success but shares slightly lower - +1.3 GSK Director Wendy Becker Joins Tesco Board as Non-Executive
Director takes Tesco non-executive role - −0.8 GSK stock at EUR 20.59 with volume 70.2 percent below average
Routine share price note with low volume - +0.8 AstraZeneca vs GSK: Comparing Two UK Stocks in AI-Driven Healthcare
Comparison with AstraZeneca, largely neutral
GSK: every day · Pharma and healthcare on 9 October 2026 · FTSE 100 overview for the day